廣告
香港股市 將在 30 分鐘 開市

  • 恒指

    17,716.47
    -373.46 (-2.06%)
     

  • 國指

    6,324.05
    -153.19 (-2.37%)
     

  • 上證綜指

    2,945.85
    -26.67 (-0.90%)
     

  • 道指

    39,164.06
    +36.26 (+0.09%)
     

  • 標普 500

    5,482.87
    +4.97 (+0.09%)
     

  • 納指

    17,858.68
    +53.53 (+0.30%)
     

  • Vix指數

    12.24
    -0.31 (-2.47%)
     

  • 富時100

    8,179.68
    -45.65 (-0.55%)
     

  • 紐約期油

    81.98
    +0.24 (+0.29%)
     

  • 金價

    2,334.30
    -2.30 (-0.10%)
     

  • 美元

    7.8082
    -0.0006 (-0.01%)
     

  • 人民幣

    0.9303
    0.0000 (0.00%)
     

  • 日圓

    0.0483
    -0.0001 (-0.12%)
     

  • 歐元

    8.3536
    -0.0042 (-0.05%)
     

  • Bitcoin

    61,467.71
    +517.40 (+0.85%)
     

  • CMC Crypto 200

    1,281.31
    +15.17 (+1.20%)
     

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks Equity Research
·2 分鐘文章

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why This 1 Growth Stock Should Be On Your Watchlist

Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

廣告

DaVita HealthCare (DVA)

Denver, CO-headquartered DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

DVA boasts a Growth Style Score of B and VGM Score of A, and holds a Zacks Rank #2 (Buy) rating. Its bottom-line is projected to rise 13.6% year-over-year for 2024, while Wall Street anticipates its top line to improve by 5%.

Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.39 to $9.62 per share. DVA boasts an average earnings surprise of 29.4%.

DaVita HealthCare is also cash rich. The company has generated cash flow growth of 4.9%, and is expected to report cash flow expansion of 12.5% in 2024.

With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, DVA should be on investors' short lists.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

DaVita Inc. (DVA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research